Cargando…

Methodological Characteristics of Clinical Trials Supporting the Marketing Authorisation of Advanced Therapies in the European Union

Several advanced therapy medicinal products (ATMPs) have been approved in the European Union (EU). The aim of this study is to analyse the methodological features of the clinical trials (CT) that supported the marketing authorization (MA) of the approved ATMPs in the EU. A systematic review of the c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iglesias-Lopez, Carolina, Agustí, Antònia, Vallano, Antonio, Obach, Merce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668425/ https://www.ncbi.nlm.nih.gov/pubmed/34916948 http://dx.doi.org/10.3389/fphar.2021.773712

Ejemplares similares

Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States
por: Iglesias-Lopez, Carolina, et al.
Publicado: (2019)

Corrigendum: Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States
por: Iglesias-Lopez, Carolina, et al.
Publicado: (2020)

The challenges of access to innovative medicines with limited evidence in the European Union
por: Vallano, Antonio, et al.
Publicado: (2023)

Current landscape of clinical development and approval of advanced therapies
por: Iglesias-Lopez, Carolina, et al.
Publicado: (2021)

The work of the European Union Reference Laboratory for Food Additives (EURL) and its support for the authorisation process of feed additives in the European Union: a review
por: von Holst, Christoph, et al.
Publicado: (2016)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012
por: Lane, Samantha, et al.
Publicado: (2018)

Description of the Risk Management of Medication Errors for Centrally Authorised Products in the European Union
por: Hoeve, Christina E., et al.
Publicado: (2019)

The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children
por: Kreeftmeijer-Vegter, Annemarie Rosan, et al.
Publicado: (2014)

Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders
por: Mulder, Jorn, et al.
Publicado: (2021)

The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines
por: Cavaleri, Marco, et al.
Publicado: (2021)

Additional Risk Minimisation Measures for Medicinal Products in the European Union: A Review of the Implementation and Effectiveness of Measures in the United Kingdom by One Marketing Authorisation Holder
por: Agyemang, Elaine, et al.
Publicado: (2017)

Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?
por: Jaeger, Simon U, et al.
Publicado: (2022)

Valorising and Creating Access to Innovative Medicines in the European Union
por: Annemans, Lieven, et al.
Publicado: (2011)

Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs
por: Giannuzzi, Viviana, et al.
Publicado: (2017)

Proposal for authorisation to derogate from the standard procurement framework applicable at CERN for projects partially funded by the European Union
Publicado: (2015)

Proposal for authorisation to derogate from the standard procurement framework applicable at CERN for projects partially funded by the European Union
Publicado: (2015)

Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency
por: Collignon, Olivier, et al.
Publicado: (2018)

Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies
por: Elvira, David, et al.
Publicado: (2021)

Cell-based medicinal products approved in the European Union: current evidence and perspectives
por: Bellino, Stefania, et al.
Publicado: (2023)

Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
por: Pontes, Caridad, et al.
Publicado: (2018)

Impact of Amending the Acetylcysteine Marketing Authorisation on Treatment of Paracetamol Overdose
por: Thompson, G., et al.
Publicado: (2013)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Visit of Thierry Breton, Commissioner for Internal Market of the European Union
por: Cavazza, Marina
Publicado: (2023)

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
por: Car, Elif, et al.
Publicado: (2023)

Experiences and Perspectives of Marketing Authorisation Holders towards Medication Safety Monitoring during Pregnancy: A Pan-European Qualitative Analysis
por: Sillis, Laure, et al.
Publicado: (2022)

Market Integration and Price Dynamics under Market Shocks in European Union Internal and External Cheese Export Markets
por: Xue, Huidan, et al.
Publicado: (2022)

Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut)
por: Guarga, Laura, et al.
Publicado: (2019)

An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe
por: Ebbers, Hans C., et al.
Publicado: (2015)

EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation
por: Detela, Giulia, et al.
Publicado: (2019)

GANIL authorised
Publicado: (1975)

Clinical Trial Authorisation: A Final Look Back to Better Appraise the New European Regulation
por: Vignot, Stéphane, et al.
Publicado: (2023)

Recent Advances in Pharmaceutical Cocrystals: From Bench to Market
por: Kumar Bandaru, Ravi, et al.
Publicado: (2021)

Turning Meadow Weeds Into Valuable Species for the Romanian Ethnomedicine While Complying With the Environmentally Friendly Farming Requirements of the European Union’s Common Agricultural Policy
por: Grosu, Elena, et al.
Publicado: (2020)

Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis
por: Ivama-Brummell, Adriana M., et al.
Publicado: (2023)

Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013–2017
por: Brown, Jeremy Philip, et al.
Publicado: (2019)

Adverse Drug Reactions in Pediatric Oncohematology: A Systematic Review
por: Amaro-Hosey, Kristopher, et al.
Publicado: (2022)

Advanced Computational Methodologies Used in the Discovery of New Natural Anticancer Compounds
por: Chavda, Vivek P., et al.
Publicado: (2021)

A European strategic “third way?” The European Union between the traditional transatlantic alliance and the pull of the Chinese market
por: Casarini, Nicola
Publicado: (2022)

Guidance on the renewal of the authorisation of feed additives
por: Bampidis, Vasileios, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oroqsqs00l1u0om9stqtj24alk